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1. Introduction 
In isolated pancreatic islets, we found that insulin 
biosynthesis and release were stimulated by addition 
of glucagon [l] whereas insulin release could be inhib- 
ited by exogenous somatostatin [2,3] but not by 
insulin itself [4]. On the other hand, in attempts to 
bind endogenous islet hormones by incubating islets 
with corresponding antisera, conflicting results con- 
cerning insulin release were obtained with anti-somato- 
statin serum [5,6]. No such data were available about 
the influence of endogenous islet hormones on insulin 
biosynthesis or somatostatin release. Therefore, we 
decided to study insulin biosynthesis and &lease as 
well as somatostatin release from isolated rat islets 
during incubation with antisera against glucagon, 
somatostatin and insulin. 
2. Material and methods 
Islets were isolated by collagenase from the pan- 
creata of male rats (strain FW 49 Lemgo-Kirchb.-Bib.) 
fed ad libitum. Batches of 20 islets were incubated in 
1 ml gassed, supplemented Krebs-Ringer-bicarbonate 
buffer (pII 7.4) at 50 or 300 mg/lOO ml glucose 
together with [311]leucine (50 /Xi) and the hormone 
antisera or normal control sera (see below). Hormone 
release was determined in aliquots of the incubation 
media by radioimmunoassay. (Pro-)Insulin biosyn- 
thesis was estimated from incorporation data for 
[311]leucine into the proinsulin and insulin fraction 
of the islet proteins after extraction and fractionation 
on a Sephadex G-50 column. All these procedures 
were performed as in [ 11. 
Rabbit antiglucagon serum (K30) was purchased 
ElsevierfNorth-Holbznd Biomedical Press 
from Serono, Freiburg (lot no. 2903-l). The 3.5 ~1 of 
this antiserum which were added to 1 ml incubation 
medium exhibited a binding capacity of 2.5 ng gluca- 
gon. Anti-somatostatin serum from the rabbit was a 
gift of Professor Arnold, Gijttingen. The 5 ~1 of this 
antiserum added to 1 ml medium bound 10 ng somato- 
statin. Guinea pig antiserum to bovine insulin was 
raised by Dr Bretzel from our group. The 5 1.11 anti- 
serum used in 1 ml medium bound 5 mU (-200 ng) 
insulin. 
Statistical evaluations were carried out by the 
paired or unpaired Student’s t-test. 
3. Results 
Presence of anti-glucagon serum resulted in a sig- 
nificant reduction of both glucose-stimulated insulin 
release and biosynthesis. At the sub-stimulatory glu- 
cose level of 50 mg/lOO ml, no changes were observed 
(fig.1). Glucose-stimulated somatostatin release was 
significantly depressed in the presence of anti-glucagon 
serum (table 1). 
With anti-somatostatin serum, an enhancement of 
insulin release provoked by 300 mg glucose/ 100 ml 
was found whereas insulin release at 50 mg glucose/ 
100 ml and proinsulin-insulin biosynthesis at both 
glucose levels did not change (fig.2). 
As was expected and can be seen from fig.3, no 
insulin was measurable by immunoassay in the media 
in which anti-insulin serum was present during the 
incubations. Glucose (300 mg/lOO ml)-stimulated 
proinsulin-insulin biosynthesis was found to be 
unchanged. There was also no significant difference 
in glucose-stimulated somatostatin release: It 
amounted to 107 f 10 and 172 * 20 pg/20 islets after 
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Fig.2. Influence of antisomatostatin serum on insulin release 
(upper part) and proinsulin-insulin biosynthesis (black and 
open bars, respectively; lower part). IsoIated rat islets were 
incubated for 3 h at 50 or 300 mg glucose/100 ml together 
with anti-~matostatin serum from the rabbit (iASS) or 
normal rabbit serum. Mean +_ SEM, n = 7. 
Fig.1. Influence of anti-glucagon serum on insulin release 
(upper part) and proinsulir-insulin biosynthesis (black and 
open bars, respectively; lower part). Isolated rat islets were 
incubated for 3 h at 50 or 300 mg giucose/lOO ml together 
with ~ti~lucagon serum from the rabbit (+AGS) or normal 
rabbit serum. Mean + SEM, n = 7. 
(fig.1) and also somatostatin release (table I). Such 
local effects have long been assumed to exist from the 
results of studies on the influence of added exogeneous 
glucagon on the regulation of both the B-cell (cf. [ 11) 
and D-cell function [7-91, and also from morphologic 
findings [lo], A decrease in insulin release in the pres- 
I and 3 h in the controls and to 89 4 15 and 22.5 + 
42 pg/20 islets after 1 and 3 h in the presence of anti- 
insulin serum, respectively (mean + SEM, n = 12). 
4. Discussion 
It thus appears that endogenous glucagon is indeed 
involved by focal (~aracrine) action in regulation of 
insulin release as well as (pro-)insu~n biosynthesis 
Table 1 
Somatostatin (pg) secreted mto the incubation media of 
20 isolated rat islets incubated for 3 h in the presence of 
rabbit antiglucagon serum or normal rabbit serum (controls) 
~-- 
Glucose Mean f SEM,n = 12 
(mg/lOO ml) 
Controls Anti-glucagon serum 
GPS AIS GPS AIS 
Fig.3. Influence of anti-insulin serum on (pro-)insulin bio- 
synthesis. Left, insulin measured by radioimmunoassay in the 
media; right, proinsulin (P)-insulin (i) biosynthesis. Isolated 
rat islets were incubated for 3 h at 50 or 300 mg glucose/ 
100 ml alone or together with guinea pig ~ti-insulin serum 
(+AIS) or normal guinea pig serum (GPS). Mean + SEM, 
n = 11-16. 
50 175 * 29 207 t 30 
p < 0.01 
300 290 i 28 p < 0.01 184 t 23 
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ence of anti-glucagon serum has also been reported in 
abstract form, however, no effect at high glucose con- 
centration was found [ 111. 
Our result that glucose stimulates somatostatin 
release (table 1) confirms the findings in [ 12,131, 
however, it is at variance with those of in [6,14]. The 
increase of glucose-stimulated insulin release but not 
of biosynthesis observed in the presence of anti- 
somatostatin serum (fig.2) agrees with current views 
on the involvement of somatostatin in regulation of 
B-cell function; whereas insulin release is obviously 
controlled by the hormone of the D-cells (cf. [ 15]), 
this appears not to be the case for (pro-)insulin bio- 
synthesis (unpublished, [16-181, but cf. [19]). In 
[S ,201 an increase in insulin release with antisomato- 
statin serum was also observed but only at a sub-stim- 
ulatory or intermediate but not at high glucose concen- 
tration. However, the experimental design in [5,20] 
differed from ours; they preincubated the islets with 
the antiserum and tested insulin release thereafter 
without antiserum in the presence of glucose or/and 
leucine only. Work with precultured rat islets [6] 
revealed no influence of anti-somatostatin serum on 
insulin output. But in [6], addition of somatostatin 
also did not change insulin release from the islets. 
To our experience, antisera against somatostatin 
should always be tested for cross-reactivity against 
glucagon. In contrast to the anti-somatostatin serum 
used here, a commercially available anti-somatostatin 
serum (which we had taken for a first series of exper- 
iments) bound, to our surprise, large amounts of glu- 
cagon, although synthetic somatostatin had been used 
for immunisation according to the information given 
by the producer. 
The presence of insulin antibodies and the binding 
of all secreted insulin by anti-insulin serum did not 
influence (pro-)insulin biosynthesis (fig.3), arguing 
against an immediate feedback inhibition of insulin 
secretion on its own synthesis [4,21], an action which 
has been claimed, however for proinsulin [22]. Indi- 
rect evidence for the absence of such a direct, nega- 
tive feedback emerges also from studies of the effects 
of addition of insulin antibodies to the culture media 
of islets [23]. The fact that there was no significant 
change in somatostatin release in the presence of anti- 
insulin serum might be taken as an argument against 
a local (paracrine) influence of insulin on somato- 
statin release. Such a notion would agree with numer- 
ous negative results obtained with exogenous insulin 
concerning somatostatin secretion ([7,9,15] but cf. 
[241). 
It can be concluded that, by local action: 
1. Endogenous glucagon stimulates insulin biosyn- 
thesis and release as well as somatostatin release; 
2. Somatostatin reduces release but not biosynthesis 
of insulin; and 
3. Insulin has no direct action on its own biosynthe- 
sis. No influence of insulin on somatostatin release 
is apparent. 
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